Advertisement

Topics

Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

19:00 EDT 27 Jul 2017 | Net Resources International

Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six.

Original Article: Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection

NEXT ARTICLE

More From BioPortfolio on "Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection"

Quick Search
Advertisement
 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...